Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features

NCT04429334 is registered in ClinicalTrials.gov with Inotrem as lead sponsor.

NCT NCT04429334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04429334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features
Lead sponsor
Inotrem
Phase
Phase 2
Overall status
Completed
Start date
September 23, 2020
Completion date
June 22, 2022
Enrollment
220 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

covid19